197 related articles for article (PubMed ID: 33658617)
21. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.
Smith EM; Zhang L; Walker BA; Davenport EL; Aronson LI; Krige D; Hooftman L; Drummond AH; Morgan GJ; Davies FE
Oncotarget; 2015 Jul; 6(19):17314-27. PubMed ID: 26015393
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
[TBL] [Abstract][Full Text] [Related]
24. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
25. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.
Singh MM; Johnson B; Venkatarayan A; Flores ER; Zhang J; Su X; Barton M; Lang F; Chandra J
Neuro Oncol; 2015 Nov; 17(11):1463-73. PubMed ID: 25795306
[TBL] [Abstract][Full Text] [Related]
26. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
27. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Sakamoto T; Ozaki K; Fujio K; Kajikawa SH; Uesato S; Watanabe K; Tanimura S; Koji T; Kohno M
Biochem Biophys Res Commun; 2013 Apr; 433(4):456-62. PubMed ID: 23501104
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
[TBL] [Abstract][Full Text] [Related]
29. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
30. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
[TBL] [Abstract][Full Text] [Related]
31. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Booth L; Roberts JL; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
[TBL] [Abstract][Full Text] [Related]
32. A dual and conflicting role for imiquimod in inflammation: A TLR7 agonist and a cAMP phosphodiesterase inhibitor.
Ernst O; Failayev H; Athamna M; He H; Tsfadia Y; Zor T
Biochem Pharmacol; 2020 Dec; 182():114206. PubMed ID: 32828805
[TBL] [Abstract][Full Text] [Related]
33. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
34. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
35. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.
He L; Torres-Lockhart K; Forster N; Ramakrishnan S; Greninger P; Garnett MJ; McDermott U; Rothenberg SM; Benes CH; Ellisen LW
Cancer Discov; 2013 Mar; 3(3):324-37. PubMed ID: 23274910
[TBL] [Abstract][Full Text] [Related]
36. Formation of HERV-K and HERV-Fc1 Envelope Family Members is Suppressed on Transcriptional and Translational Level.
Gröger V; Wieland L; Naumann M; Meinecke AC; Meinhardt B; Rossner S; Ihling C; Emmer A; Staege MS; Cynis H
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113941
[TBL] [Abstract][Full Text] [Related]
37. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
39. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
40. Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
Makena MR; Nguyen TH; Koneru B; Hindle A; Chen WH; Verlekar DU; Kang MH; Reynolds CP
Anticancer Drugs; 2021 Jan; 32(1):34-43. PubMed ID: 33079733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]